Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year

“The new NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profile of belapectin. We continue to see encouraging consistency across key biomarkers-including FibroScan, ELF, and PRO-C3-all supporting belapectin’s durable antifibrotic activity and potential to slow disease progression in patients with compensated MASH cirrhosis. We submitted the NAVIGATE data package to the FDA and requested feedback on proposed next steps, with guidance anticipated by year-end. As we move forward, our focus remains on advancing dialogue with FDA and exploring strategic opportunities to maximize the value of this promising program,” said Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics (GALT).